Finasteride

Clinical Summary

Finasteride is a selective Type II 5α-reductase inhibitor. It blocks conversion of testosterone to dihydrotestosterone (DHT) in androgen-dependent tissues (scalp, prostate), sparing the Type I isoform that dominates liver, skin, and CNS. At 1 mg/day it produces ~65-70% serum DHT suppression and maintains or regrows scalp hair in roughly 80-90% of men with androgenetic alopecia (AGA) when used continuously for ≥12 months. At 5 mg/day it reduces prostate volume ~20% and symptom progression in benign prostatic hyperplasia (BPH), and cuts risk of acute urinary retention and BPH-related surgery (PMID 14681504 MTOPS).

It is one of the most studied drugs in dermatology and urology with over 25 years of trial data and >57,000 FAERS reports. Efficacy for AGA and BPH is not in serious dispute. What IS in dispute is the frequency and nature of persistent adverse effects after discontinuation — post-finasteride syndrome (PFS) — encompassing persistent sexual dysfunction, depression, anhedonia, cognitive slowing, and anxiety. MHRA (April 2024), EMA (May 2025), and FDA (2022 Propecia label) have all updated labels to reflect suicidality signals, while cohort meta-analyses (PMID 38692949 Uleri 2024; PMID 28319231 Welk 2017) find no cohort-level association. Both datasets are real; both framings are partial.

Who benefits most: men with documented AGA (Norwood II-V) willing to commit to multi-year use and monitor for sexual/psychiatric side effects; men ≥50 with symptomatic BPH (prostate >30 mL or PSA >1.5 ng/mL) per AUA 2023 guidelines (PMID 37706750). Who should be cautious: men <35 with any history of depression, anxiety, or sexual dysfunction; anyone planning conception soon (semen parameters may shift); women of reproductive age (Category X teratogenicity).

Topical 0.25% solution — now supported by Phase 3 data in European (PMID 34634163 Piraccini) and Chinese (PMID 40090937 Zhou 2026) populations — offers comparable efficacy with ~100× lower plasma exposure. It is the most interesting development of the last 2 years because it preserves efficacy while materially reducing the risk surface that drives the PFS debate.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence. BH = Bradford Hill causal strength (/9). Safety flag reflects FAERS/trial signals for this specific indication.

Type codes: DC=Direct causation | PC=Probable causation | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS/trial safety signal — see Safety section | AVOID Contraindicated for this indication

Why oral-AGA is flagged WARN: AGA-indication reports concentrate in younger men (18-44) where FAERS sexual and neuropsychiatric signals are strongest (PMID 40473994, 40082195). Same compound at same dose carries MON for BPH because older patients have different baseline risk profile and the efficacy window is larger.

Prescribing

Dosing Table

Formulation Table

Condition-Specific Protocols

Androgenetic Alopecia Protocol

Evidence: 5/5 | Key PMID: 35107565 (Gupta 2022 NMA), 34634163 (topical), 40090937 (topical China 2026)

Phase 1: Initiation (Weeks 1-4)

• Oral: 1 mg/day OR topical 0.25%, 1 mL/day
• Baseline photos (vertex, mid-scalp, hairline, temples) under consistent lighting
• Optional baseline labs: total T, SHBG, DHT, TSH, ferritin, 25-OH-D (rule out non-androgenic hair loss)
• Expected: transient "dread shed" weeks 2-8 (synchronized telogen exit) — DO NOT stop; this is often a response indicator
• Monitor: note any mood, libido, or cognitive change and log weekly

Phase 2: Therapeutic (Weeks 5-52)

• Continue same dose
• Repeat photos at 3, 6, 12 months under identical conditions
• Expected: shedding slows weeks 8-12; visible density improvement weeks 16-24; terminal hair regrowth 6-12 mo
• Peak visible effect: 12-18 months
• If any persistent sexual, cognitive, or mood change at any checkpoint → stop and reassess (see Stop Criteria below)

Phase 3: Maintenance (Year 2+)

• Continue indefinitely — benefits reverse within 6-12 months of discontinuation
• Annual photo review; rescan for mood/sexual/cognitive drift
• If tolerating but plateauing: consider adding topical minoxidil 5% (PMID 32166351 — combo > either alone) or switching to dutasteride 0.5 mg EOD (more DHT suppression, more side-effect risk)

Drug Interaction Timing: No significant enzymatic interactions. Tadalafil 5 mg PRN can be co-administered (now co-formulated for BPH). Topical minoxidil applied separately from topical finasteride; 2-4 h spacing prevents dilution issues.

Expected Outcomes:

• Serum DHT: −65 to 70% at 1 mg oral within 2 weeks (assay requires LC-MS; standard RIA is too noisy)
• Scalp DHT: −55 to 65%
• Hair count vertex: +10 to +30 hairs/cm² at 12 months
• Plasma finasteride at topical 0.25%: 100× lower than oral (PMID 34634163)

Stop/Reassess Criteria:

• New-onset depressive symptoms, anhedonia, suicidal ideation → STOP immediately, consult physician
• Persistent sexual dysfunction >2 weeks at any dose → STOP, reassess
• Testicular pain (rare) → STOP, urology referral
• Gynecomastia (1-2% incidence) → endocrinology workup; may be reversible
• No visible hair response at 12 months → reconsider diagnosis (alopecia areata, telogen effluvium, scarring alopecia, nutritional)

BPH Protocol (5 mg)

Evidence: 5/5 | Key PMID: 14681504 (MTOPS), 40683564 (5-yr), 37706750 (AUA 2023)

Phase 1: Initiation (Weeks 1-12)

• 5 mg/day
• Baseline: PSA (before starting), prostate volume, IPSS symptom score
• Expected: early symptom relief modest; full effect at 6-12 months

Phase 2: Therapeutic (Months 3-12)

• Continue 5 mg/day
• Consider adding alpha-blocker (tamsulosin, silodosin) for rapid symptom relief — MTOPS showed combo superior to either alone (−66% progression vs −34% finasteride alone)
• Repeat PSA at 6 months — double measured value for prostate-cancer screening purposes
• Symptom reassessment at 6 and 12 months (IPSS)

Phase 3: Maintenance (Year 2+)

• Continue indefinitely or until surgical decision
• Annual PSA, IPSS, prostate volume
• Long-term 5-yr data (PMID 40683564) show symptom improvement comparable to Rezūm water-vapor therapy

Drug Interaction Timing: Tadalafil 5 mg once daily is FDA-approved combination (Novitium 2025, ANDA218499) — addresses ED that may pre-exist or emerge on therapy.

Expected Outcomes:

• PSA: −50% (halves) at 6-12 months — DOUBLE measured value for screening
• Prostate volume: −15-25% at 12 months
• IPSS symptom score: −3 to −5 points at 12 months
• Acute urinary retention risk: −57% (MTOPS)

Stop/Reassess Criteria:

• PSA rising above baseline (after the expected 50% drop) → urology referral (doubled PSA trend indicates possible cancer)
• New sexual dysfunction beyond baseline BPH profile → discuss topical-only or dutasteride switch
• Any neuropsychiatric change → STOP and reassess

Safety

Interactions Table

Contraindications

• Women of reproductive potential (Category X)
• Pediatric patients (not studied)
• Hypersensitivity to finasteride
• Active depression or suicidality (relative — careful case-by-case)
• Pre-existing sexual dysfunction unexplained by comorbidity (relative)
• Concurrent use of other persistent-dysfunction drugs without full counseling (relative — SSRIs, isotretinoin)

Adverse Effects (ranked by frequency — RCT vs FAERS)

From RCTs (placebo-controlled):

• Decreased libido: 1-6% attributable (counseling-sensitive — Mondaini study showed 3× higher with explicit counseling vs blind)
• Erectile dysfunction: 1-5% attributable
• Ejaculation disorder (reduced volume, watery): 1-2%
• Breast tenderness/enlargement: 0.5-1%
• Rash: <1%

From FAERS (real-world, voluntary, skewed):

• Erectile dysfunction: 4,057 reports
• Fatigue: 4,018
• Depression: 3,591
• Anxiety: 3,064
• Sexual dysfunction: 2,365
• Libido decreased + loss of libido: 3,259
• Cognitive disorder: 1,570
• Suicidal ideation: 1,533
• Completed suicide: 346
• Gynecomastia: 638
• Death (as outcome): 3,884

The gap between RCT rates (<5%) and FAERS reporting volumes reflects the voluntary nature of FAERS, selection bias toward harm, advocacy-driven reporting surges (2024+ MHRA/EMA reviews), and possible real signal obscured by low-power RCT safety endpoints. The truth is somewhere between "effectively benign" and "universally harmful."

FAERS Signal Table (from BioMCP, cumulative through Q1 2026)

Reading FAERS data: These are spontaneous voluntary reports, not incidence rates. Absolute incidence of persistent symptoms is genuinely unknown — estimates range from <1% (pharmacovigilance-adjusted) to double-digit percentages (PFS-cohort self-reports). The 21% post-2024 surge reflects MHRA/EMA reviews and advocacy — interpret as signal validation, not as incidence.

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Women of Reproductive Age

• Category X: absolute contraindication. Male fetus external genital abnormalities reported with in-utero exposure. Handling broken or crushed tablets is also contraindicated. Intact coated tablets are safe to handle.
• Postmenopausal off-label use: 2.5-5 mg/day used for FPHL and FFA. Breast cancer cohort study (PMID 39326790) showed no excess risk in a Northwestern cohort — preliminary and reassuring but small.
• Semen for conception: paternal exposure to finasteride has not been shown to harm offspring; semen finasteride concentrations are orders of magnitude below teratogenic threshold. However, reduced semen volume (~11%) and subjective decreased fertility reports warrant discussion if conception is the goal.

Young Men (<35)

• Highest FAERS signal concentration for sexual and neuropsychiatric AEs
• Consider topical 0.25% as first-line systemic-sparing option
• Thorough pre-treatment counseling about PFS debate (without inflating OR dismissing)
• Mood and sexual function baseline documentation before initiation

Elderly (>70, BPH context)

• Fall risk signal (FAERS 1,771) likely reflects BPH-patient demographics, not drug effect
• Standard 5 mg dose
• Be alert to cognitive decline complaints — rarely reversible if truly drug-related

Synergies & Stacking

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo/nocebo effects, and recall bias are inherent. Two parallel realities exist online — r/tressless (maintenance works, sides rare) vs PFS Foundation / propeciahelp (life-altering persistence). Neither is representative of the full user base.

Dominant Sentiment

Polarized across ~hundreds of thousands of reports. r/tressless (500k+ subs, mixed-positive) vs propeciahelp.com (5,000+ registered, severely negative). r/FinasterideSyndrome vocal adverse community. Mainstream biohacker/nootropic forums trend cautious/skeptical.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: None direct, but hair-loss telehealth (Hims, Keeps, Ro/Roman) operates affiliate-style on influencer YouTube (Haircafe, Brett Maverick). WSJ investigation documented under-disclosure of sexual AEs in telehealth ads (regulatory loophole vs drugmaker disclosure obligations).
• Influencer concentration: Strong — 3-5 YouTube dermatology influencers drive ~60% of visible hair-loss content, almost all with telehealth affiliate deals.
• Astroturfing signals (pro-fin): Low-workup telehealth prescribing; boilerplate "1-2% side effect rate"; minimization of neurosteroid mechanism.
• Astroturfing signals (anti-fin): Symptom-list bloat (every general-population complaint attributed); universal-permanence claims without cohort data; fundraising overlays on symptom pages.
• Commercial bias: Positive before/after pictures on telehealth sites are curated; survivor bias in r/tressless (unsuccessful users tend to leave forums).

Folk vs Clinical Reality Check

Where community experience ALIGNS with clinical data: efficacy for AGA is real (community progress pictures match trial hair-count data); sexual side effects do occur (rates contested but presence is not); tolerability improves with topical vs oral (matches PMID 40662444 FAERS analysis). Where it DIVERGES: the PFS prevalence claim on propeciahelp (double-digit % persistent symptoms) is not replicated in cohort epidemiology (<1% adjusted); symptom-list breadth often exceeds plausible finasteride mechanism (vision changes, back pain, etc. likely represent general-population symptom attribution). Most likely explanation for divergence: bidirectional selection bias — successful users vanish from forums, harmed users congregate on PFS communities — combined with real nocebo effect documented by Mondaini (3× counseling amplification) AND a real minority experiencing genuine persistent pharmacological effects. Both can be true.

Deep Dive: Mechanisms & Research

Mechanism (clinical translation confirmed): Finasteride selectively inhibits Type II 5α-reductase (SRD5A2), expressed in androgen-dependent tissues (prostate, scalp hair follicle dermal papilla, genital skin). It converts testosterone → 5α-dihydrotestosterone (DHT). At 1 mg/day, serum DHT falls ~65-70%; scalp DHT falls ~55-65%. Prostate DHT falls ~80-90% at 5 mg/day. Type I 5α-reductase (SRD5A1) — expressed in liver, brain, non-genital skin — is largely spared by finasteride (dutasteride inhibits both).

Neurosteroid implication (partial clinical translation, mechanistic basis for PFS hypothesis): 5α-reductase converts progesterone → 5α-DHP → allopregnanolone (a positive allosteric GABA-A modulator) and deoxycorticosterone → THDOC. Because finasteride mostly spares SRD5A1 in CNS, the plasma-level allopregnanolone reduction is modest at 1 mg, but any reduction in a minority of users with constitutively low baseline may cross a clinical threshold. This is the leading mechanistic hypothesis for the neurosteroid component of PFS (PMID 41718149 Rodriguez-Cerdeira 2026 PRISMA review).

Pharmacokinetics: Oral bioavailability ~65%; Tmax 1-2 h; plasma half-life 6-8 h (longer in elderly); metabolized by CYP3A4; no active metabolites relevant for efficacy. Scalp and prostate DHT suppression outlasts plasma half-life because the enzyme rebinds substrate competitively — this is why alternate-day or 3×/week dosing is pharmacokinetically defensible (though not RCT-validated).

Topical absorption: At 0.25%, plasma finasteride is ~100× lower than oral 1 mg; serum DHT suppression 30-40% vs 65-70% oral; scalp DHT suppression comparable. This is the rationale for topical as side-effect-sparing alternative (PMID 34634163).

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Total registered trials: ~60 (condition search) / 91 (intervention search). Completed: ~38. Active/recruiting: 4-7 depending on query. Notable gap: no dedicated RCT on low-dose oral protocols (1 mg MWF, 0.5 mg/day).

Regulatory Status (from BioMCP)

• FDA: Approved 1992 (Proscar 5 mg, BPH; NDA020180) and 1997 (Propecia 1 mg, AGA; NDA020788). Most recent supplementary approvals: Proscar SUPPL 50 (2026-03-18), Propecia SUPPL 30 (2022-08-01). Finasteride + tadalafil combination capsule (Novitium NDA218499) approved 2025-03-19 for BPH. 2022 Propecia PI update added suicidality as ADR (depression added 2011). April 2025 FDA alert on compounded topical finasteride (telehealth channel).
• EMA: National authorizations (no centralized record per BioMCP). May 2025 PRAC concluded multi-year safety review, acknowledged suicidal ideation as side effect of finasteride 1 mg and 5 mg; EU-wide patient alert card required.
• MHRA (UK): April 2024 Drug Safety Update with patient alert card requirement, triggered by 426 Yellow Card sexual-dysfunction reports and 281 depressive-mood/suicidal-behavior reports accumulated since early 1990s.
• PMDA (Japan): Approved 2005 as Propecia (MSD); widely prescribed standard of care.
• Regulatory context: Regulatory divergence around persistent adverse effects has tightened substantially 2024-2025. This is a compound where safety framing has shifted during your career, not a static label.

Ataraxia Verdict (as of 2026-04-18)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to popularity: "Millions of men have taken this" — does not rule out rare serious AEs concentrated in susceptible minority. Flag when used to dismiss PFS concerns.
• Cherry-picking: Industry-adjacent literature (Gupta/Mediprobe, Farjo Hair Institute) emphasizes nocebo; regulatory/PFS-critical literature (Brezis, Lee) emphasizes real signal. Reading one cluster only gives half the picture.
• Hasty generalization: Extrapolation from RCT safety endpoints (underpowered for rare persistent AEs) to "effectively benign" overreaches. Conversely, extrapolation from self-selected PFS forums to general incidence overreaches the other direction.
• Appeal to nature: "Try saw palmetto first" — saw palmetto is a weaker 5-AR inhibitor with same mechanism. Not a safer alternative, just less effective.
• Confounded attribution: PFS forum reports attribute many general-population symptoms (fatigue, back pain, vision) to finasteride. Some are real drug effects; some are baseline.

Evidence Gaps

• No dedicated RCT on low-dose oral protocols (1 mg MWF, 0.5 mg/day, 0.25 mg/day)
• No large placebo-controlled RCT on frontal fibrosing alopecia
• No genotype-guided prospective trial on SRD5A2 variants as response predictor (NCT06944145 partial — raloxifene alternative in SRD5A2-absent men, results 2030)
• No long-term (>5 yr) data on topical 0.25% safety and durability
• PFS prevalence in population-representative cohort: unknown (ranges <1% to double digits depending on source)
• Mechanistic biomarker for PFS susceptibility (neurosteroid panel? AR epigenetic markers?): not validated
• Dose-response for persistent AEs: unknown whether risk scales with dose or is threshold-binary
• Fertility/semen parameter effects: limited data at 1 mg
• Transgender care: essentially unstudied in RCT format despite clinical use

Bias Flags (Mode 4: First Principles)

• Industry/authorship bias: Gupta (Mediprobe Research) and Farjo Hair Institute-affiliated analyses consistently frame PFS as nocebo. Authors have dermatology-practice conflicts of interest. Not wrong on data, but framing is partial.
• Regulatory capture critique: Brezis 2025 (PMID 41004169) argues FDA/EMA delayed PFS recognition ~20 years; FAERS accumulation patterns are consistent with delayed regulatory response.
• Litigation-driven reporting: class-action lawsuits amplify FAERS reporting independently of actual incidence.
• Publication venue bias: urology journals (Eur Urol Focus, J Urol) trend pro-finasteride; some psychiatric journals (J Clin Psychiatry) trend more precautionary.
• First principles read: Finasteride is genuinely effective and genuinely carries real risk of persistent symptoms in a minority. The size of that minority is unsettled. Both "safe as aspirin" and "pharma thalidomide 2.0" framings fail first-principles scrutiny.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Pharma (Organon for Propecia) and generic manufacturers benefit from continued prescribing volume. 2022 FDA-mandated suicidality labeling only partially propagated to patient inserts per PFS Foundation. Telehealth (Hims, Keeps, Ro) is the dominant 2025-2026 acquisition channel with formal regulatory concerns about ad disclosure under-disclosure (WSJ exposé).
• Influencer economics: Dermatology-adjacent YouTube (Haircafe, Brett Maverick) operates on Hims/Keeps affiliate deals. "1-2% side effect rate" is boilerplate; rarely cite FAERS. Conversely, anti-finasteride content clusters on PFS Foundation donation funnels and alternative-treatment sellers (RU58841, expensive peptide stacks, hair-transplant upsells).
• Counter-narrative manipulation: PFS Foundation legitimately advocates for label changes but symptom-list bloat (vision changes, musculoskeletal pain, etc.) weakens credibility. Anti-finasteride content sometimes conflates finasteride with dutasteride (stronger inhibitor) to amplify risk appearance.
• Cui bono summary: Pro-finasteride winners = Organon/generics + telehealth + dermatology clinics + hair-care industrial complex. Anti-finasteride winners = plaintiff bar (class-action) + alternative-treatment sellers + PFS Foundation donation streams. Pharma's PR incentive is to downplay persistent risk; activist incentive is to inflate it. Both distortions coexist in the public conversation.
• Red team highlight: The most concerning angle is the young-adult AGA cohort — this is a cosmetic indication with lifetime exposure horizon, and FAERS psychiatric signals cluster exactly there. If real incidence is even 1-2% for serious persistent AEs (between cohort null result and PFS forum claims), the absolute count of life-altering harm per year is substantial given the millions of prescriptions. This is why MHRA and EMA acted.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 7/10 — very high efficacy for two real medical indications (AGA, BPH); offset by real risk of rare but life-altering persistent AEs in a minority, particularly young adults. This is NOT a "wellness" supplement — it is a targeted pharmaceutical with a clear benefit-risk calculation required per user.
• Opportunity cost: Minimal financial cost ($5-15/mo generic). Complexity cost is low (once-daily tablet). Attention cost is moderate — ongoing self-monitoring for mood/sexual/cognitive changes is required, not optional. For BPH in older men, opportunity cost is dominated by the condition itself (alternatives include surgery and alpha-blockers). For AGA in young men, opportunity cost includes the irreversibility risk of persistent AEs in the subset that experiences them.
• Verdict: CONDITIONAL
• Conditions:
  • For AGA: moderate-to-severe hair loss (Norwood II-V or female equivalent) that is psychologically meaningful to the user, willingness to monitor mood/sexual/cognitive function monthly, no active depression or anxiety disorder, and strong preference for topical 0.25% as first-line if under 35. Consider full counseling about PFS debate BEFORE starting, not after.
  • For BPH: prostate volume >30 mL or PSA >1.5 ng/mL per AUA 2023, symptomatic LUTS, after shared decision-making about surgical vs medical options. Combination with alpha-blocker for high-progression-risk patients.
  • For frontal fibrosing alopecia or female-pattern hair loss: after dermatology consultation, with explicit off-label counseling.
  • NOT for: general "longevity" or "prostate health" indication without documented BPH; recreational scalp maintenance without significant AGA; any user unwilling to accept the non-zero risk of persistent sexual/neuropsychiatric symptoms.

Bottom Line

Finasteride is one of the most effective and best-studied pharmaceutical interventions for androgenetic alopecia and benign prostatic hyperplasia. For the right patient, it works — tens of millions of prescriptions and decades of data confirm this. But it is not benign. A real minority of users — most concentrated in young AGA patients — experience persistent sexual, psychiatric, or cognitive symptoms that may outlast discontinuation. The size of that minority is genuinely unknown (between cohort-null-result and PFS-forum-claim). MHRA (2024), EMA (2025), and FDA (2022) have all tightened safety framing in the last 24 months, and this is not noise — it reflects accumulating signal. The honest read is: if you have documented AGA or BPH and understand the risk, oral finasteride is a reasonable option; topical 0.25% is a strictly-better first-line for AGA in young men; any new mood, sexual, or cognitive symptom is grounds to stop and reassess, not push through. Do not take finasteride for cosmetic mild hair thinning if you have a history of depression or anxiety. Full stop.

Practical Notes

Brands & Product Selection

• Oral (AGA): Generic finasteride 1 mg is bioequivalent to Propecia. Choose pharmacy with good generic sourcing (Accord, Teva, Ivax, Gedeon Richter all have ANDAs). Propecia branding does not confer efficacy advantage.
• Oral (BPH): Generic 5 mg is bioequivalent to Proscar. Pill-splitting from 5 mg for AGA is a well-established cost hack (~$2/mo) but accuracy of splits varies — pill splitter recommended, not teeth.
• Topical: Compounded 0.25% solution is the mainstream formulation. Sources: specialty compounding pharmacies (ask for LC-MS content verification), telehealth platforms (Hims, Keeps, Ro), or commercial brands (Finasteridefoam, Topical Finasteride by Pelage in EU). FDA April 2025 alert on compounded topical sprays — prefer solution/liquid formats with clear concentration labeling.
• Combination products: Finasteride + minoxidil topical kits available; finasteride + tadalafil oral (Novitium 2025) for BPH + ED.
• Red flags: Unlabeled or unverified compounding sources; "enhanced" formulations with unverified mesolytic enhancers; telehealth platforms that skip workup.

Storage & Handling

• Room temperature 20-25°C; protect from light and moisture
• Tablets coated — safe handling for intact tablets
• NEVER crush or break tablets in household with pregnant or potentially-pregnant women present
• Shelf life 3 years per label; topical compounded solutions 6 months typically
• No refrigeration required

Palatability & Compliance

• Once-daily dosing — one of the easier compliance profiles
• No taste issues (tablet)
• Habit stack: morning tablet with toothbrushing, supplement routine, or coffee
• Topical: apply at night after scalp is dry; hands must be washed after application if partner/others in household
• Miss a dose: do not double; skip and resume next day

Exercise & Circadian Timing

• No evidence that timing matters for efficacy
• Some users report fewer sexual sides with evening dosing (no RCT)
• No interaction with exercise
• Testosterone-modulating context: if using with TRT, monitor for elevated T (DHT shunting) and emotional/body composition shifts

Reference Ranges (Expected Biomarker Changes)

Cost

• Generic 1 mg: $5-15/mo (~$0.17-0.50/day)
• Brand Propecia: $30-50/mo
• Generic 5 mg split for AGA: ~$2/mo (cost-optimal if pill splitter used accurately)
• Compounded topical 0.25%: $35-80/mo
• Telehealth packages (Hims/Keeps/Ro): $20-40/mo — trades cost savings for minimal workup
• Full workup (dermatology + labs + prescription): $200-500 upfront + ongoing drug cost

What We Don't Know

• Absolute prevalence of persistent post-discontinuation symptoms in an unselected, representative cohort
• Who is pharmacogenomically susceptible (SRD5A2 variants, AR CAG length, baseline neurosteroid status)
• Whether persistent AE risk scales with dose, duration, or is a threshold effect
• Long-term (>5 yr) safety of topical 0.25% in free-living populations
• Whether low-dose oral protocols (1 mg MWF, 0.5 mg/day) preserve efficacy and reduce AE rate (no RCT)
• Whether the "unknown indication" 44% of FAERS reports masks a true AGA vs BPH risk split
• Mechanism of persistent AEs: allopregnanolone suppression is plausible but not proven causal
• Whether PFS represents a unified syndrome or heterogeneous cluster of drug-related and unrelated conditions
• Whether rechallenge identifies a susceptible subpopulation (small French case series suggests yes)
• Fertility and semen parameter effects at 1 mg over multi-year exposure
• Hair graying reversal claims (zero published evidence; circulating community anecdote)
• Ultimate Gleason 8-10 signal interpretation (biological vs detection bias)

References

Systematic Reviews & Meta-Analyses

• PMID 35107565 — Gupta AK et al. JAMA Dermatol 2022. Network meta-analysis, minoxidil + 5-ARIs for AGA. Dutasteride 0.5 mg ranked most effective at 24 wk; finasteride 5 mg best at 48 wk.
• PMID 38725143 — Gupta 2024 NMA. Updated AGA monotherapy ranking.
• PMID 41051009 — Gupta 2025 NMA. Confirmed oral/topical finasteride efficacy.
• PMID 32166351 — Chen 2020 meta. Finasteride + topical minoxidil > either monotherapy.
• PMID 30206635 — Lee 2019 meta. 5-ARIs 1.57× sexual dysfunction vs placebo.
• PMID 30863034 — Zhou 2019 review. Dutasteride ≥ finasteride for AGA.
• PMID 29797431 — Gupta 2018 NMA non-surgical AGA.
• PMID 28396101 — Adil 2017 JAAD. AGA treatment effectiveness review.
• PMID 27225981 — van Zuuren 2016 Cochrane. Interventions for female pattern hair loss.
• PMID 39749123 — Dutasteride vs finasteride review (2025).
• PMID 41127390 — China meta 2025, topical fin+minoxidil > minoxidil alone.
• PMID 41502115 — 2026 meta, 30 RCTs (n=2,974). TURP pre-op blood loss −82.58 mL.
• PMID 39944628 — Finasteride bladder cancer incidence ↓ (HR 0.75).

Landmark RCTs

• PMID 12824459 — Thompson NEJM 2003, PCPT n=18,882. −24.8% prostate cancer incidence.
• PMID 23944298 — PCPT 18-year follow-up. No OS difference.
• PMID 30673548 — PCPT mortality long-term follow-up 2019.
• PMID 14681504 — McConnell NEJM 2003, MTOPS n=3,047. Combination reduced progression 66% vs placebo.
• PMID 40683564 — MTOPS 5-yr follow-up vs Rezūm (2025).
• PMID 34634163 — Piraccini Phase 3 topical finasteride Europe (n=458).
• PMID 40090937 — Zhou 2026 Chinese Phase 3 topical finasteride (n=270, NCT05135468).
• PMID 41874081 — Piraccini 52-wk real-world topical 0.25% (n=146, Bologna).
• PMID 39496123 — Karachi RCT topical 0.25% + minoxidil (n=164).
• PMID 40208341 — Indonesia RCT topical 0.1% + minoxidil (n=40).

Mechanism & Neurosteroid

• PMID 41718149 — Rodriguez-Cerdeira 2026 PRISMA review, SRD5A isoforms and neurosteroid hypothesis.
• PMID 40377688 — Rat model chronic finasteride (2025), LTP and behavior.
• PMID 12042668 — SRD5A2 V89L lower 5-AR activity (2002).
• PMID 17448593 — SRD5A2 variants and aggressive prostate cancer (2007).
• PMID 27164191 — PCPT genotype substudy.
• PMID 31776447 — Germline variation PCPT/SELECT.

Post-Finasteride Syndrome

• PMID 32033719 — Traish 2020 Fertil Steril. PFS clinical framework.
• PMID 39953145 — Cilio 2025 Int J Impot Res. PFS as true clinical entity critical review.
• PMID 37697052 — Leliefeld 2025 Int J Impot Res. PFS mechanisms and symptoms.
• PMID 34719438 — Healy 2022. Enduring sexual dysfunction diagnostic criteria.
• PMID 34247957 — Howell 2021 J Sex Med. PFS gene expression.
• PMID 32951160 — Borgo 2021. PFS gut microbiota (pilot).
• PMID 37993021 — Giatti 2024 Front Neuroendocrinol. PFS/PSSD overlap.
• PMID 31559258 — Trüeb 2019. Contrarian view (mass psychogenic illness hypothesis).
• PMID 39934554 — Stachelek 2025. Peripheral nature of post-finasteride/SSRI/isotretinoin.
• PMID 29733030 — Healy 2018. 300-case series.
• PMID 41865985 — Moreno-Arrones 2026. Spanish dermatologist survey on PFS.
• PMID 41027755 — Géniaux 2025 French BNPV. 40 depression/suicidality cases without sexual dysfunction.

Depression & Suicidality

• PMID 32869255 — Deng 2020 Urol J. 5-ARIs mild depression increase (finasteride ns).
• PMID 38692949 — Uleri 2024 Eur Urol Focus. Meta n=2.2M, no significant association.
• PMID 40473994 — Lee 2025 Eur J Clin Pharmacol. Pharmacovigilance ≥35M reports: suicidality ROR 7.28.
• PMID 40732247 — FAERS 2015-2024 Bayesian analysis.
• PMID 40082195 — Gupta 2025. Pre-PFS vs post-PFS era ROR (reporting bias argument).
• PMID 41524216 — Gupta 2026. Oral vs dutasteride nocebo framing.
• PMID 41004169 — Brezis 2025 J Clin Psychiatry. Failing public health critique.
• PMID 28319231 — Welk 2017 JAMA Intern Med. Ontario cohort n=93,197 — self-harm HR 1.88.
• PMID 40584531 — NHANES+FAERS cognition signal aOR 6.15.
• PMID 40127098 — Zhong 2025 PLoS One FAERS n=11,557.
• PMID 40971937 — Wu 2025 J Sex Med. Finasteride highest sexual-dysfunction ROR 212.3.
• PMID 40662444 — Gupta 2026. Topical vs oral pharmacovigilance.
• PMID 41876378 — FAERS 2026 disproportionality BPH drugs.

Women / Pregnancy / FPHL

• PMID 39326790 — Venkatesh 2025 Northwestern. Women breast cancer cohort.
• PMID 37650533 — Iran RCT 2024. Topical minoxidil + spironolactone vs + finasteride in women.
• PMID 37386777 — FPHL NMA 5-ARI + minoxidil > minoxidil alone.

Off-label / Other

• PMID 37691183 — Finasteride vs hydroxychloroquine in FFA RCT.
• PMID 39800209 — JAAD 2026 FFA review. 5-ARIs first-line systemic.

Gynecomastia & Breast Cancer

• PMID 8778596 — Green 1996 NEJM. Index gynecomastia/MBC case series.
• PMID 28228662 — Hagberg 2017. No MBC association.
• PMID 31126837 — Fang 2019 breast disease database.

Guidelines

• PMID 37706750 — Sandhu AUA 2024 BPH amendment.
• PMID 41997777 — Baboudjian EAU 2026 Male LUTS summary.
• PMID 29863806 — Manabe JDA 2018 male/female-pattern hair loss.

East Asian Data

• PMID 21980923 — Sato 2012 Japanese n=3,177, 2.5 yr.
• PMID 25903108 — Yoshitake 2015 Japanese n=801, 5 yr.
• PMID 38833144 — Korean IVL3001 long-acting injectable PK/PD.
• PMID 40251992 — Br J Dermatol 2025. East Asian hair density genetics.
• PMID 41622844 — CG2001 Phase 1 Chinese AGA.

Nocebo / Vulnerability

• PMID 17655657 — Mondaini 2007. 3× counseling effect on sexual AEs.
• Rivetti 2025 J Cosmet Dermatol — Pre-existing vulnerability framework.